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Abstract
Background: Mesolimbic and nigrostriatal dopaminergic pathways play important roles in both the rewarding and
conditioning effects of drugs. The dopamine transporter (DAT) is of central importance in regulating dopaminergic
neurotransmission and in particular in activating the striatal D2-like receptors. Molecular imaging studies of the
relationship between DAT availability/dopamine synthesis capacity and active cigarette smoking have shown
conflicting results. Through the collaboration between 13 SPECT centres located in 10 different European countries,
a database of FP-CIT-binding in healthy controls was established. We used the database to test the hypothesis that
striatal DAT availability is changed in active smokers compared to non-smokers and ex-smokers.
Methods: A total of 129 healthy volunteers were included. Subjects were divided into three categories according
to past and present tobacco smoking: (1) non-smokers (n = 64), (2) ex-smokers (n = 39) and (3) active smokers
(n = 26). For imaging of the DAT availability, we used [123I]FP-CIT (DaTSCAN) and single photon emission computed
tomography (SPECT). Data were collected in collaboration between 13 SPECT centres located in 10 different
European countries. The striatal measure of DAT availability was analyzed in a multiple regression model with age,
SPECT centre and smoking as predictor.
Results: There was no statistically significant difference in DAT availability between the groups of active smokers,
ex-smokers and non-smokers (p = 0.34). Further, we could not demonstrate a significant association between
striatal DAT and the number of cigarettes per day or total lifetime cigarette packages in smokers and ex-smokers.
Conclusion: Our results do not support the hypothesis that large differences in striatal DAT availability are present
in smokers compared to ex-smokers and healthy volunteers with no history of smoking.
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Background
The behavioural and neurobiological effects of smoking
are similar to those of other addictive substances [1],
and several studies have demonstrated the involvement
of the mesolimbic dopaminergic system in mediating
the response to cigarette smoking or nicotine intake.
Nicotine-induced dopamine release has been demon-
strated in rodents [2-4] and non-human primates [5-8].
These findings have been indirectly supported by several
positron emission tomography (PET) studies where
decreases of [11C]raclopride binding (thought to reflect
increases in the extracellular concentration of dopamine)
in the ventral striatum/nucleus accumbens following
smoking [6,9-12] or nicotine intake [13] were observed.
PET-studies, using radiopharmaceuticals for the dopamine
D2/3 receptors, have demonstrated significant associations
between dopamine release and reduction in craving [9,10],
enhancement of pleasure [14,15] and the severity of
nicotine dependence [12]. However, the reduction in D2/3
binding upon smoking compared to the baseline condition
is modest (5% to 10%) in these studies compared to that
following cocaine (20% to 30%) [16] and amphetamine
[17-19]. Such an effect of 5% to 10% is similar to the test-
retest variability of molecular imaging techniques using
PET and SPECT [20-22] and may be difficult to demon-
strate in PET and SPECT studies using small data samples.
This may explain the failure of some PET studies to dem-
onstrate changes in [11C]raclopride binding upon nicotine
administration [14,15]. Dopamine release in the ventral
striatum/nucleus accumbens has been demonstrated to be
directly mediated through the binding of nicotine to α4β2
nAChRs leading to an increase in firing rate in dopamine
neurons of the ventral tegmental area [23,24]. Previous
human imaging studies do not provide strong support
for the idea that postsynaptic dopamine D2/3 receptor
availability is affected by chronic exposure to cigarette
smoke. A reduced dopamine D2/3 receptor availability
was demonstrated in the putamen in men [25], but not in
woman [26]. Two SPECT studies failed to demonstrate
changes in striatal dopamine D2/3 receptor availability in
smokers compared to non-smokers [27,28].
The dopamine transporter (DAT) provides the primary
mechanism through which dopamine is cleared from the
extracellular fluid after its release from the presynaptic
cell. However, only few studies have addressed the effect
of chronic dosing of nicotine on the DAT [29]. Nicotine
is not a competitor nor a substrate for DAT [30], and
it does not bind to a site on the DAT protein [31].
Nicotine appears to induce changes in DAT function
by indirect mechanisms which include both augmentation
(enhancing amphetamine-induced reverse transport of
dopamine by DAT) and reduction (increase in cell surface
DAT expression) of dopaminergic neurotransmission [32].
Human imaging studies of DAT availability in relation to
chronic tobacco smoking are sparse and have generated
conflicting results [28,33] possibly related to methodo-
logical problems including the choice of radioligand and
sample size. We studied the DAT availability using [123I]
FP-CIT-SPECT in a group of 26 active smokers, 39
ex-smokers and 64 subjects with no history of smoking.
We tested the hypothesis that DAT availability is changed
in active smokers compared to ex-smokers and subjects
with no history of tobacco smoking. Understanding
the mechanisms underlying the neurobiological effects
of nicotine on the regulation of DAT may have the po-
tential to translate into new and possibly individualized
treatment strategies.
Methods
Participants
The European Normal Control Database of DaTSCAN
(ENCDAT) study is an initiative taken by the Neuroimaging
Committee of the European Association of Nuclear
Medicine (EANM). The database was established through
the collaboration between 13 SPECT centres located in 10
different European countries. The centres were selected
by EANM based on their involvement in SPECT imaging
of the dopaminergic system and their high level of experi-
ence and quality of brain SPECT imaging. The protocol
was approved by the medical ethical committees of all
participating centers and was performed in accordance
with the ethical standards of the Declaration of Helsinki.
All subjects gave written informed consent to participate
in the study.
In this study, 129 of the available ENCDAT healthy
volunteers (all Caucasian) were included. Twelve healthy
volunteers had to be excluded because no imaging data
for the scatter windows data were available, and ten
healthy volunteers (ex-smokers) had to be excluded
because of lifetime usage of less than 60 packages of
cigarettes. Our sample had a balanced male-to-female
ratio (70 males and 59 females), and the age range was
20 to 83 years (>20 per decade, expected for ages
between 80 to 90 years). The distribution between the
participating centres was as follows: Amsterdam (n = 9),
Ankara (n = 10), Copenhagen (n = 13), Genoa (n = 14),
Leipzig (n = 13), Leuven (n = 16), London (n = 10),
Munich (n = 11), Nice (n = 4), Southampton (n = 3),
Stockholm (n = 13) and Yvoir (n = 13).
Inclusion criteria were the following:
 No history of parkinsonism in first-degree relatives
 No medication known to affect DAT binding
 Absence of psychiatric symptoms as evaluated by
the following: Symptom Checklist-90-R score < 63,
Beck Depression Inventory score ≤ 9 and
Mini-Mental State Examination ≥ 28
 Negative urine screening for drugs (ten drugs)
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 Body temperature ≤ 38.5°C on the day of scanning
 Negative pregnancy test in premenopausal females
Smoking data
All subjects were interviewed about tobacco smoking
habits (as part of the inclusion criteria) and were quantified
through The Copenhagen Smoking Questionnaire [34].
Data regarding the time of the last cigarette before
scanning was not available. Subjects were divided into
three categories according to past and present tobacco
smoking habits: (1) non-smokers (n = 64), (2) ex-smokers
(more than 60 total numbers of packages in lifetime, n = 39)
and (3) active smokers (1 to 30 cigarettes per day, n = 26),
as shown in Table 1. Ten of the active smokers used more
than 15 cigarettes per day. For smokers, the cigarette use
per day was registered, and for all smokers (active smokers
and ex-smokers), the total number of packages in lifetime
was registered.
Data acquisition and reconstruction
Data acquisition was performed according to the
ENCDAT protocol (EANM Research Ltd. (EARL)/
European Network of Excellence for Brain Imaging)
using the scanners and collimators specified in the
ENCDAT protocol. All camera systems had passed elab-
orate quality control and phantom measurements [35].
SPECT acquisition was started 3 to 4 h after an average
intravenous bolus of 180.5 MBq (range 152 to 215 MBq)
of [123I]FP-CIT (GE Healthcare, Amersham, UK). Image
reconstruction was carried out at a core centre using the
HERMES HOSEM software (HERMES Medical Solutions,
Stockholm, Sweden), using iterative reconstruction with
10 subsets and 10 iterations for 120 projections and 8 sub-
sets and 12 iterations for 128 projections to give a similar
number of EM equivalent iterations [36]. Reconstructions
were performed with attenuation and scatter corrections
using the triple-energy window method. After reconstruc-
tion, images were smoothed on the HERMES workstation
with a 3D Butterworth filter (cut-off 1.2 cm–1, order 10).
ROI delineation and SBR calculation
We used the ratio of specifically bound radioligand to that
of nondisplaceable radioligand in tissue (specific binding
ratio (SBR)) calculated between 3 and 4 h after tracer
injection as a measure of the DAT availability [37]. Regions
of interest (ROIs) were delineated, and SBR was calculated
using DATquan (Figure 1) [38]. DATquan offers a fast, ac-
curate, and highly reproducible method for semi-automatic
VOI delineation using a template-based approach.
Results
For the study of the association between DAT measure-
ments and smoking habits, we used a priori a linear model
where we adjusted for age, which has previously been iden-
tified as an important confounder. Data were collected from
several different centers, and to account for potential cluster
effects, we therefore used a random intercept model.
In general, similar results were obtained from a more
parsimonious model for the clustering based on marginal
models with robust standard errors (i.e., a generalized
estimating equation framework). Here, we only report
results (maximum likelihood estimates) from the random
intercept model.
Variance homogeneity of residuals across the different
centers was tested using a likelihood ratio test which
indicated that this assumption was reasonable (p = 0.77).
In all cases, residual analysis revealed that a log transform-
ation of the DAT measurements was favorable (all results
based on the log transformation and hence parameters
can be interpreted as log relative differences). However,
quite similar conclusions were reached based on modeling
of the data on their original scale. Linearity of the con-
tinuous predictor age was assessed using a linear mixed
additive model and by inclusion of polynomial terms in
the model. R version 2.15 was used for all analyses [39],
http://www.R-project.org/).
Active smoking was not associated with any statisti-
cally significant effects on the striatal DAT availability
compared to non-smokers (7.7% lower DAT availability,
95% confidence limits (−17.3%, 3.0%), p = 0.15); the
same was true for DAT availability in caudate nucleus
(95% confidence limits (−16.7%, 3.2%), p = 0.17) and puta-
men (95% confidence limits (−17.5%, 3.9%), p = 0.19). There
was no statistically significant difference in DAT availability
between the groups of active smokers, ex-smokers and
non-smokers (p = 0.34) as seen in Figure 2.
There was a clear effect of age on DAT availability
with an age decline in striatum equal to 4.6% per decade
(95% confidence limits (−6.9%, −2.2%)), in line with a previ-
ous study [40]. The estimated residual standard deviation
within clusters was 0.228, and the standard deviation of the
random intercept (between clusters) was 0.115.
Table 1 Age and smoking habits for 129 healthy volunteers
Number Mean age ± SD
(range) in years
Current average number of
cigarettes per day ± SD (range)
Total number of packages
in lifetime mean (range)
Non-smokers 64 (34 males) 51.7 ± 18.5 (20 to 81) 0 0
Ex-smokers 39 (21 males) 59.2 ± 15.4 (25 to 83) 0 4,497 (66 to 28,220)
Active smokers 26 (15 males) 47.2 ± 19.4 (21 to 79) 11.2 ± 8.6 (1 to 30) 5,991 (60 to 24,630)
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As seen in Figure 3, there was no statistically significant
association between striatal DAT availability and numbers
of cigarettes per day (in smokers) with an estimated 5.6%
decrease in DAT availability per ten cigarettes per day
((−12.6%, 1.3%), p = 0.114); furthermore, we found no
negative correlation between total cigarette packages in
lifetimes and striatal DAT availability (0.6% decrease in
DAT availability per 1,000 packages, 95% confidence limits
(1.4%, 0.3%), p = 0.20) in caudate nucleus (p = 0.21) and
putamen (p = 0.19). There was no statistically significant
Figure 1 Two horizontal slices from the constructed [123I]-FP-CIT template. Illustrating exact position and configuration of the reference
(left) and striatal (right) ROIs.
Figure 2 Association between striatal DAT availability and smoking status. The vertical bars shows the estimated mean within each group with 95%
confidence limits as estimated by a random intercept model (with a variance component defined by the centre) adjusting for age at scan (reference, mean
age = 53 years). Individual points are partial residuals (i.e., best linear unbiased predictor of the residuals plus the estimated intercept within each group).
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difference in striatal DAT availability (p = 0.906) in ex-
smokers compared to non-smokers and in ex-smokers
compared to active smokers (p = 0.152).
Discussion
In this large sample, we did not observe any statistically
significant effect of tobacco smoking on striatal DAT
availability as measured with [123I]FP-CIT SPECT in active
smokers (n = 26) and ex-smokers (n = 39) compared to
non-smokers (n = 64). In addition, a statistically significant
association between striatal DAT availability and numbers
of cigarettes per day or total cigarette packages in lifetimes
was not found. Our results in active smokers compared to
ex-smokers do not support the idea of changed striatal
DAT availability upon daily nicotine administration.
However, the possible acute effect of smoking on striatal
DAT availability still needs to be explored.
This study is in line with the results of Staley et al. which
did not demonstrate changes in striatal [123I]β-CIT
binding in 21 smokers compared to 21 non-smokers
[41]. [123I]β-CIT binds to both the striatal DAT and the
serotonin transporter (SERT), and the non-selectivity
of this tracer hampers the conclusions to be drawn
from this study on the relative role of DAT compared
to SERT in smoking. A recent study by Erritzoe et al.
also failed to demonstrate significant differences in the
binding of the PET tracer [11C]DASB to SERT in
smokers compared to non-smokers [34]. Our study
does not replicate the findings of a decreased striatal
DAT availability in smokers [28,33] using [99mTc]
TRODAT-1 SPECT. We believe that the discrepancies
between the findings in the two [99mTc]TRODAT-1
SPECT studies and the results of our study and the
study of Staley et al. [41] are related to the sample size
(8 and 11 active smokers were included in the [99mTc]
TRODAT-1 SPECT studies) and possibly the imaging
properties of [99mTc]TRODAT-1 related to a small ratio
between binding of tracer in striatum compared to the
reference region leading to data being more susceptible to
noise. In a [18F]fluorodopa PET of the striatal presynaptic
dopamine activity in active smokers (n = 9) compared to
non-smokers (n = 10), a significantly higher uptake of
striatal [18F]fluorodopa was demonstrated in smokers
compared to non-smokers [42]. A higher uptake of
[18F]fluorodopa is generally interpreted as a result of
an increased dopamine synthesis capacity. However, a
Figure 3 Estimated association between log (striatal DAT availability) and number of cigarettes per day (currently). With 95% pointwise
confidence limits as estimated by a random intercept model adjusting for age (reference, mean age = 53 years). Individual points are the partial
residuals, defined as the best linear unbiased predictor of the residuals plus the estimated cigarettes per day effect.
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higher uptake of [18F]fluorodopa may be tracing several in-
dependent processes including BBB transport, competition
with other amino acids for transport, uptake into neurons,
decarboxylation to fluorodopamine and trapping within
neuronal vesicles [43]. Thus, in addition to the small
sample of active smokers in the [18F]fluorodopa PET
study, the outcome parameter is not directly comparable
to studies using radiotracers binding to the DAT.
This study has some limitations. (1) As seen in Table 1,
the numbers of cigarettes smoked per day range from 1
to 30 cigarettes, and 10 of the subjects smoked more
than 15 cigarettes per day. Thus, the group of heavy
smokers is small. However, the DAT availability in the
group smoking more than 15 cigarettes a day was not
significantly different from ex-smokers and non-smokers.
Furthermore, a statistical significant association between
cigarettes smoked per day and DAT availability was not
demonstrated (Figure 3), and according to our data, we
would expect a very small decrease in striatal DAT of 0.6%
if an individual consumed an additional 1,000 packages.
(2) We did not control for passive smoking. However,
based upon our dose–response data, we find it unlikely
that passive smoking results in detectable changes in DAT
availability in any of the three groups. (3) Though our data
sample is larger than the previous studies on DAT
availability in smoking, the study is still underpowered
to detect subtle changes in DAT availability related to
its variation between subjects and a [123I]FP-CIT
SPECT test-retest variability of approximately 10%.
Though not statistically significant, a trend toward a
decrease in DAT availability (5.6% decrease in DAT
availability per ten cigarettes per day, p = 0.114) was
found. Our study may be underpowered to demonstrate a
small effect. (4) In this multi-centre study, information
regarding time of last cigarette smoked before injection
of the radiotracer and information regarding nicotine
dependence, smoking urges and passive smoking was not
available. Future studies must address the acute effects of
cigarette smoking and thus explain whether DAT binding
predisposes to current smoking or whether current smok-
ing influences DAT binding. In contrast to the current
study using cross-sectional design, future studies could
benefit from a longitudinal design testing DAT availability
in patients before and after smoking cessation.
Conclusion
No statistically significant effect of chronic tobacco
smoking on striatal DAT availability or changes in DAT
availability in previous smokers compared to subjects
with no history of smoking was seen with [123I]FP-CIT
SPECT. With the limitations underlined in the discussion,
our data do not suggest that changes in the dopaminergic
system resulting from smoking and/or nicotine administra-
tion involve any regulatory changes in DAT. Further studies
are needed to address whether the DAT availability is
susceptible to acute smoking or nicotine administration.
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